Highly Novel Drugs Outperformed Less Novel Drugs In Gross And Net Revenues In The US, Driven Primarily By Utilization, 2013–19

Health Affairs · Published 2026-08-01 · DOI 10.1377/hlthaff.2026.00054

Authors (3)

Boshen Jiao, Ian S. Haworth, Darius N. Lakdawalla

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Jiao, B., Haworth, I., Lakdawalla, D. (2026). Highly Novel Drugs Outperformed Less Novel Drugs In Gross And Net Revenues In The US, Driven Primarily By Utilization, 2013–19. Health Affairs. https://doi.org/10.1377/hlthaff.2026.00054

Related articles

• The Extent Of Gender/Sex Variables Included In Clinical Algorithms Across Medical Specialties · Health Affairs · 2026 · Same journal
• Participatory Systems Science To Identify Local Adaptation Strategies For Extreme Heat In King County, Washington · Health Affairs · 2026 · Same journal
• Health Insurance As Climate Adaptation: A Practical Framework · Health Affairs · 2026 · Same journal
• The Uneven Distribution Of Patient Portal Messages Across Patients And Physicians · Health Affairs · 2026 · Same journal
• Who Pays When Temperatures Soar? · Health Affairs · 2026 · Same journal
• Errata · Health Affairs · 2026 · Same journal
• Rhode Island’s Affordability Standards Led To Substantial Reductions In Hospital Staffing And Labor Costs By 2022 · Health Affairs · 2026 · Same journal
• Cold-Related Illness In An Era Of Extreme Climate Events: US Trends, 1998–2022 · Health Affairs · 2026 · Same journal
• Health Care Workers In A Storm’s Path · Health Affairs · 2026 · Same journal
• The South Had The Lowest Rates Of Hospice And Palliative Medicine–Certified Providers In The US, 2024 · Health Affairs · 2026 · Same journal